

August 12, 2022

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--	---

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

This has reference to our intimation dated August 2, 2022.

The Board of Directors of the Company at its meeting held today i.e. August 12, 2022, inter alia, approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2022.



A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1.

The Board meeting commenced at 12:30 p.m. (IST) and concluded at 3:30 p.m. (IST).

This is for your information and record please.

Encl.: a/a

Thanking You,
For **Camlin Fine Sciences Limited**



Rahul Sawale
Company Secretary
& VP Legal

Registered Office:

In G.S. Point, Floor 2-5, Plot No. VIII, Private layout Scheme, C.S.T. Road, Opp. University Campus, Santacruz (E),
Mumbai – 400 098, India. | | CIN: : L74100MH1993PLC075361 | | ISO 22000 Certified Company

Tel. 022-67001000 | Fax: 022-28324404 | | Email: secretarial@camlinfo.com | | Website:www.camlinfo.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Rs. in Lakh, except per share data)

PART I		PARTICULARS	STANDALONE				CONSOLIDATED			
			QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
			30.06.2022	31.03.2022	30.06.2021	31.03.2022	30.06.2022	31.03.2022	30.06.2021	31.03.2022
			(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
1	Revenue from operations	15,543.85	20,139.00	14,572.85	68,550.81	38,377.49	38,922.50	33,082.64	1,41,208.91	
2	Other income	1,273.61	755.84	383.20	1,870.44	102.57	2,131.80	1,054.96	3,303.42	
3	Total income	16,817.46	20,894.84	14,956.05	70,421.25	38,480.06	41,054.30	34,137.60	1,44,512.33	
4	Expenses									
	Cost of materials consumed	8,176.01	10,206.71	7,965.38	38,216.64	21,143.52	19,202.00	19,328.26	72,760.09	
	Purchase of stock in trade	43.00	437.27	277.23	762.07	684.85	1,479.93	1,325.98	4,530.31	
	Changes in inventories of finished goods/WIP/stock in trade	(389.46)	(185.61)	246.03	471.50	(4,014.55)	(405.38)	(2,354.75)	(1,340.97)	
	Employee benefits expense	1,401.21	1,320.10	1,130.09	5,288.87	4,112.01	3,775.49	3,275.77	14,504.81	
	Finance costs	1,558.31	988.58	960.64	3,342.68	1,872.89	975.71	1,013.24	3,576.61	
	Depreciation and amortisation expense	727.75	689.82	644.09	2,668.28	1,437.20	1,594.10	1,341.14	5,596.47	
	Other expenses	4,784.86	5,232.46	3,036.04	16,063.50	11,789.30	12,437.74	6,950.83	35,473.83	
	Total Expenses	16,301.68	18,689.33	14,259.50	66,813.54	37,025.22	39,059.59	30,880.47	1,35,101.15	
5	Profit before exceptional items and share of profit / (loss) of associate (3-4)	515.78	2,205.51	696.55	3,607.71	1,454.84	1,994.71	3,257.13	9,411.18	
6	Exceptional items	-	-	-	-	-	-	-	-	
7	Profit before share of profit / (loss) of associate (5-6)	515.78	2,205.51	696.55	3,607.71	1,454.84	1,994.71	3,257.13	9,411.18	
8	Share of profit / (loss) of associate	-	-	-	-	-	3.64	(2.40)	(13.33)	
9	Profit before tax (7-8)	515.78	2,205.51	696.55	3,607.71	1,454.84	1,998.35	3,254.73	9,397.85	
10	Tax Expenses									
	- Current tax	93.63	383.82	125.35	639.84	743.38	816.33	830.43	3,207.41	
	- Deferred tax	(105.33)	246.92	97.98	380.89	351.56	(150.67)	46.64	153.25	
11	Profit for the period (9-10)	527.48	1,574.77	473.22	2,586.98	359.90	1,332.69	2,377.66	6,037.19	
12	Other comprehensive income									
A	(i) Items that will not be reclassified to profit or loss									
	Remeasurements of defined benefit plans	35.32	76.47	9.03	(23.30)	35.32	76.47	9.03	(23.30)	
	Income tax relating to Items that will not be reclassified to profit or loss	(12.34)	(23.57)	(3.16)	8.14	(12.34)	(23.57)	(3.16)	8.14	
B	(i) Items that will be reclassified to profit or loss									
	Exchange differences on translating the financial statements of foreign operations					(412.13)	(370.83)	334.65	(761.40)	
	The effective portion of gains and loss on hedging instruments in a cash flow hedge	(15.42)	-	-	-	(15.42)	-	-	-	
	Income tax relating to Items that will be reclassified to profit or loss	5.39	-	-	-	5.39	-	-	-	
	Other comprehensive income	12.95	52.90	5.87	(15.16)	(399.18)	(317.93)	340.52	(776.56)	
13	Total comprehensive income for the period (11+12)	540.43	1,627.67	479.09	2,571.82	(39.28)	1,014.76	2,718.18	5,260.63	
14	Profit / (loss) attributable to:									
	(i) Owners of the Company					588.65	1,513.02	2,235.70	6,067.78	
	(ii) Non-controlling interests					(228.75)	(180.33)	141.96	(30.59)	
15	Other comprehensive income attributable to:									
	(i) Owners of the Company					(372.68)	(168.38)	130.18	(880.33)	
	(ii) Non-controlling interests					(26.50)	(149.55)	210.34	103.77	
16	Total comprehensive income attributable to:									
	(i) Owners of the Company					215.97	1,344.64	2,365.88	5,187.45	
	(ii) Non-controlling interests					(255.25)	(329.88)	352.30	73.18	
17	Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,570.38	1,569.84	1,275.91	1,569.84	1,570.38	1,569.84	1,275.91	1,569.84	
18	Other Equity				57,664.33				73,223.56	
19	Earnings per Share (EPS) (of Re.1/-each) (not annualised)									
	Basic (Rs.)	0.34	1.21	0.37	1.98	0.37	1.16	1.75	4.65	
	Diluted (Rs.)	0.33	1.18	0.31	1.94	0.37	1.14	1.48	4.56	



Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company



Notes to financial results:

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 12, 2022. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time.
- The figures for the quarter ended March 31, 2022 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2022 and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
	30.06.2022	31.03.2022	30.06.2021	31.03.2022	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Other Income	1,157.11	527.30	268.37	919.06	-	1,836.12	986.41	2,326.88
Other Expense	-	-	-	-	256.81	-	-	-
Total Exchange gain / (loss)	1,157.11	527.30	268.37	919.06	(256.81)	1,836.12	986.41	2,326.88

- Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
	30.06.2022	31.03.2022	30.06.2021	31.03.2022	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	-	-	-	-	-	-	-	-
Exchange loss	761.86	701.03	98.30	850.83	1,054.59	474.55	42.26	497.00
Total Exchange gain / (loss)	(761.86)	(701.03)	(98.30)	(850.83)	(1,054.59)	(474.55)	(42.26)	(497.00)

- Other income / Other expense for standalone and consolidated above includes net gain / (loss) on fair value changes in FCCB derivative for each reporting period as under:

Particulars	STANDALONE			
	QUARTER ENDED		YEAR ENDED	
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Other Income	-	6.27	6.81	330.10
Other Expense	(111.10)	-	-	-

- During the quarter ended June 30, 2022, the Company has issued and allotted 53,750 equity shares of Re.1 each at a premium of Rs. 49 per equity share aggregating to Rs. 26.88 lakh under Employees Stock Option Scheme, 2018 (ESOP-2018). No employee stock options have lapsed under ESOP-2018 during the quarter ended June 30, 2022. No employee stock options under ESOP-2020 have lapsed during the quarter ended June 30, 2022.
- Supreme People's Court of China vide its judgement dated February 19, 2021 had imposed a penalty of RMB 159.32 million (about USD 25 million / Rs. 18,000 lakh) including right protection cost of RMB 3.49 million (about USD 0.55 million / Rs. 390 lakh) on our JV partner Ningbo Wanglong Technology Limited (being 49% stake holder in Company's subsidiary CFS Wanglong Flavors (Ningbo) Co., Ltd. (CFSWL) & others for alleged infringement of intellectual property used in the process for manufacturing Vanillin. Further, 7% of the aforesaid penalty amounting to RMB 11.15 million (about USD 1.70 million / Rs. 1,265 lakh) had also been levied to the subsidiary Company. Consequent to the Order, as an abundant legal caution, the production of Vanillin at the subsidiary's manufacturing facility in China has been stopped till further directions of the Court. In the opinion of the management, based on the discussions with the JV Partner, the findings and allegations of the Honourable Court are not based on the facts and that the order passed by the Court is arbitrary. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Supreme People's Court of China which was heard in the month of October 2021, the decision thereof is awaited. The management is confident of a favourable decision in the retrial proceedings and that no penalty will be sustained and that consequently the production is expected to restart in a very near future. Further in terms of the shareholders' agreement dated April 28, 2017 and its subsequent amendments, Company and its subsidiary, CFSWL are indemnified against penalty and or legal consequences emanating from the violation of IP rights. Under these circumstances, no impairment of the investment value of CFSWL and or other receivables is envisaged at this juncture in standalone financial results. Similarly, no impairment of goodwill and /or property, plant and equipment is envisaged in the consolidated financial results.
- National Green Tribunal (NGT) vide its direction dated January 24, 2022 had enhanced the portion of compensation attributable to the Company for alleged violations of environmental norms of manufacturers at Tarapur MIDC to an amount of Rs. 1,712.31 lakh from Rs. 428.077 lakh. The Hon'ble Supreme Court vide its order dated April 27, 2022 has stayed the proceedings of the aforesaid directions of the NGT until the matter is heard. Further, the Hon'ble Supreme Court has directed to deposit Rs. 515.561 lakh as per initial NGT order dated September 17, 2020 (Company has already deposited Rs. 154.97 lakh on February 10, 2021) until the matter is heard. The Hon'ble Supreme Court, in case of another litigant in the same NGT matter, has granted complete stay of direction of NGT. Company has made an interim application for the modification of Hon'ble Supreme Court order dated April 27, 2022, which is pending for hearing. Based on the assessment of the management, the Company believes that it has strong grounds to defend its position against these directions and hence no provision for the compensation is considered necessary in the financial statements.
- Energy cost in subsidiary CFS Europe SpA, Italy remained at high level due to Russia-Ukraine conflict. For the quarter ended June 30, 2022, the said costs were higher by Rs. 477.86 lakh as compared to quarter ended March 31, 2022 and Rs. 2,557.79 lakh as compared to the corresponding quarter ended June 30, 2021. The impact has been recovered to some extent by increase in selling prices in the quarter ended June 30, 2022 and March 31, 2022.
- The Company's operations constitute a single business segment in Speciality Chemicals.
- Figures for previous periods have been regrouped/rearranged wherever necessary.

Place: Mumbai
Date: August 12, 2022



For Camlin Fine Sciences Limited



Ashish S. Dandekar
Chairman & Managing Director

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfo.com

www.camlinfo.com

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited,
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ, Andheri- (East).

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Camlin Fine Sciences Limited ("the Company"), for the quarter ended June 30, 2022. This statement which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable, other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Unaudited Standalone Financial Results based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Attention is drawn to the fact that the figures for the quarter ended March 31, 2022 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. We draw attention to Note 7 relating to the decision of the Supreme People's Court of China which has imposed penalty amounting to RMB 159.32 million i.e. INR 18,000 lakhs on the JV partner in the subsidiary company and others for alleged infringement of intellectual




LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

property used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1,265 lakhs which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavours (Ningbo) Co. Ltd. As an abundant legal caution, the subsidiary company has stopped the production at facility till further directions of the court. As per the terms of the shareholders' agreement dated April 28, 2017 and amendments made thereafter, the Company and its subsidiary company are indemnified against penalty and or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Honorable Court which was heard in the month October 2021, the decision thereof is awaited. In the opinion of the Management, based on the above and for reasons as more fully disclosed in the aforesaid note, no impairment of the investment value or in respect of other receivables from the subsidiary company is required.

Our conclusion is not modified in respect of the above matter.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA
PARTNER
Membership Number 127355
UDIN: 22127355AOWTPO4564**

Place: Mumbai
Date: August 12, 2022

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors
Camlin Fine Sciences Limited
WICEL, F-11/12, Opp. SEEPZ Main Gate,
Central Road, SEEPZ,
Andheri- (East), Mumbai-400096

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Camlin Fine Sciences Limited (the "Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2022 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. Attention is drawn to the fact that the figures for the 3 months ended March 31, 2022 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. We draw attention to Note 7 to the Financial Results relating to the decision of the Supreme People's Court of China which has imposed penalty amounting to RMB 159.32 million i.e. INR 18,000 lakhs on the JV partner in the subsidiary company and others for alleged infringement of intellectual property



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1,265 lakhs which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavours (Ningbo) Co. Ltd. As an abundant legal caution, the subsidiary company has stopped the production at facility till further directions of the court. As per the terms of the shareholders' agreement dated April 28, 2017 and amendments made thereafter, the Company and its subsidiary company are indemnified against penalty and or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Honorable Court which was heard in the month October 2021, the decision thereof is awaited. In the opinion of the Management, based on the above and for reasons as more fully discussed in the aforesaid note, no impairment of cash generating unit consisting of property, plant and equipment of the said subsidiary or on goodwill on consolidation in respect of the said subsidiary company is required.

Our conclusion is not modified in respect of this matter.

6. The Statement includes the results of the following entities:
- i. CFS Europe S.p.A.
 - ii. CFS Do Brasil Industria Comercio Importacao E Exportacao De Aditivos Alimenticios LTDA
 - iii. Solentus North America Inc
 - iv. CFS North America LLC
 - v. Dresen Quimica, S.A.P.I. de C.V.
 - vi. Inovel, S.A.S.
 - vii. Industrias Petrotec De Mexico S.A De C.V.
 - viii. Nuvel, S.A.C.
 - ix. Britec, S.A.
 - x. Grinel, S.R.L.
 - xi. Chemolutions Chemicals Ltd.
 - xii. CFS Wanglong Flavours (Ningbo) Co. Ltd.
 - xiii. CFS Argentina S.A.
 - xiv. CFS Chile De S.p.A
 - xv. CFS Pahang Asia Pte Ltd.
 - xvi. AlgalR NutraPharma Private Limited
 - xvii. CFS De Mexico Blends S.A.P.I. DE C.V
7. Based on our review and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
8. We did not review the interim financial results of twelve subsidiaries incorporated outside India and two subsidiaries in India included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 26,677.24 lakh, total net profit after tax of Rs. (275.49) lakh and total comprehensive income of Rs. (686.85) lakh. These interim financial results have been



reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.


In case of a subsidiary located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in its country is reviewed by another auditor under generally accepted auditing standards applicable in that country. The Company's management has converted the interim financial results of this subsidiary located outside India from accounting principles generally accepted in its country to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to the balances and affairs of this subsidiary located outside India is based on the report of the auditor and the conversion adjustments made by the management of the Company and reviewed by us.

Our conclusion on the Statement is not modified in respect of the above matters.

9. The Statement includes interim financial results of three subsidiaries incorporated outside India included in the consolidated unaudited financial results, whose interim financial results reflect total revenue of Rs. 635.65 lakh, total net profit after tax of Rs. (200.22) lakh and total comprehensive income of Rs. (237.46) lakh for the quarter ended June 30, 2022. These interim financial results of three subsidiaries are not reviewed as of the date of this report and have been included in the interim financial results on the basis of the Unaudited Management Accounts. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the Unaudited Management Accounts and other financial information furnished by the management.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA
PARTNER
Membership Number 127355
UDIN: 22127355AOWTVC7252**

Place: Mumbai
Dated: August 12, 2022

(Rs.in Lakh)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022									
No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022	30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations	15,543.85	20,139.00	14,572.85	68,550.81	38,377.49	38,922.50	33,082.64	1,41,208.91
2	Net Profit from ordinary activities after tax	527.48	1,574.77	473.22	2,586.98	359.90	1,332.69	2,377.66	6,037.19
3	Net Profit for the period after tax and non-controlling interests (after extraordinary items)					588.65	1,513.02	2,235.70	6,067.78
4	Total Comprehensive Income for the period	540.43	1,627.67	479.09	2,571.82	(39.28)	1,014.76	2,718.18	5,260.63
5	Equity Share Capital	1,570.38	1,569.84	1,275.91	1,569.84	1,570.38	1,569.84	1,275.91	1,569.84
6	Other Equity				57,664.33				73,223.56
7	Earnings per share (before and after extraordinary items) (of Re 1/-each)								
	-Basic Rs.	0.34	1.21	0.37	1.98	0.37	-1.16	1.75	4.65
	-Diluted Rs.	0.33	1.18	0.31	1.94	0.37	1.14	1.48	4.56

The above information is an extract of the detailed format of unaudited results for the quarter ended June 30, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter ended June 30, 2022 are available on the Company's website at www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

For Camlin Fine Sciences Limited



Ashish S. Dandekar
Chairman & Managing Director

Place: Mumbai
Date: August 12, 2022

CFS
Camlin
Fine Sciences

Registered Office:

Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400 093, India.
CIN: L74100MH1993PLC075361 | ISO 22000 Certified Company

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com